Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AstraZeneca plc (AZN) vs T-Rex 2X Long MSTR Daily Target ETF (MSTU) Price & Performance

AstraZeneca plcTrade
T-Rex 2X Long MSTR Daily Target ETFTrade

Price performance (Past 24H)

Key statistics

AstraZeneca plc vs T-Rex 2X Long MSTR Daily Target ETF — how do they compare? AstraZeneca plc trades at $158.59 (market cap $248.14B), while T-Rex 2X Long MSTR Daily Target ETF trades at $1.83. The key difference: AstraZeneca plc pays a 2.01% dividend while T-Rex 2X Long MSTR Daily Target ETF pays none, and AstraZeneca plc is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.

AZNMSTU
Market Cap
$248.14B
Sector
HealthLeveraged / Inverse
52-Week High
$209.48$76.30
52-Week Low
$147.06$1.46
Enterprise Value
$275.41B
Dividend Yield
2.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AstraZeneca plc

AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.

The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.

T-Rex 2X Long MSTR Daily Target ETF

MSTU, a leveraged ETF tracking MicroStrategy (MSTR), trades at $1.815, down 3.97% on the day, reflecting severe long-term erosion. The technical outlook is bearish with moving averages signaling strong selling pressure, while oscillators remain neutral. Recent news highlights catastrophic losses, including a 98% decline from 2024 levels, exacerbated by a 10:1 reverse stock split effective August 24, 2026.

The outlook for MSTU is highly risky due to leveraged decay and dependency on MSTR's volatile performance. Investment opportunities are minimal given the fund's history of value destruction, with risks including daily rebalancing losses, crypto market exposure, and lack of fundamental company metrics. Caution is paramount for potential investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN

About T-Rex 2X Long MSTR Daily Target ETF

MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.

Read more on MSTU